Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies

The role that mechanistic mathematical modeling and systems biology will play in molecular medicine and clinical development remains uncertain. In this study, mathematical modeling and sensitivity analysis were used to explore the working hypothesis that mechanistic models of human cascades, despite model uncertainty, can be computationally screened for points of fragility, and that these sensitive mechanisms could serve as therapeutic targets. We tested our working hypothesis by screening a model of the well-studied coagulation cascade, developed and validated from literature. The predicted sensitive mechanisms were then compared with the treatment literature. The model, composed of 92 proteins and 148 protein–protein interactions, was validated using 21 published datasets generated from two different quiescent in vitro coagulation models. Simulated platelet activation and thrombin generation profiles in the presence and absence of natural anticoagulants were consistent with measured values, with a mean correlation of 0.87 across all trials. Overall state sensitivity coefficients, which measure the robustness or fragility of a given mechanism, were calculated using a Monte Carlo strategy. In the absence of anticoagulants, fluid and surface phase factor X/activated factor X (fX/FXa) activity and thrombin-mediated platelet activation were found to be fragile, while fIX/FIXa and fVIII/FVIIIa activation and activity were robust. Both anti-fX/FXa and direct thrombin inhibitors are important classes of anticoagulants; for example, anti-fX/FXa inhibitors have FDA approval for the prevention of venous thromboembolism following surgical intervention and as an initial treatment for deep venous thrombosis and pulmonary embolism. Both in vitro and in vivo experimental evidence is reviewed supporting the prediction that fIX/FIXa activity is robust. When taken together, these results support our working hypothesis that computationally derived points of fragility of human relevant cascades could be used as a rational basis for target selection despite model uncertainty.

[1]  Scott L Diamond,et al.  Blood coagulation kinetics: high throughput method for real-time reaction monitoring , 2004, Thrombosis and Haemostasis.

[2]  Dougald M Monroe,et al.  A cell-based model of thrombin generation. , 2006, Seminars in thrombosis and hemostasis.

[3]  James F. Antaki,et al.  Computational Simulation of Platelet Deposition and Activation: I. Model Development and Properties , 1999, Annals of Biomedical Engineering.

[4]  H. Weiss,et al.  Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. , 1988 .

[5]  K. Mann,et al.  Biochemistry and Physiology of Blood Coagulation , 1999, Thrombosis and Haemostasis.

[6]  H. Kitano,et al.  Computational systems biology , 2002, Nature.

[7]  S L Diamond,et al.  Reaction complexity of flowing human blood. , 2001, Biophysical journal.

[8]  James F. Antaki,et al.  Computational Simulation of Platelet Deposition and Activation: II. Results for Poiseuille Flow over Collagen , 1999, Annals of Biomedical Engineering.

[9]  M Gent,et al.  Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high‐risk abdominal surgery , 2005, The British journal of surgery.

[10]  Adam P. Arkin,et al.  Statistical Construction of Chemical Reaction Mechanisms from Measured Time-Series , 1995 .

[11]  M. Samama,et al.  The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. , 1988, Thrombosis research.

[12]  A R Thompson,et al.  Structure, function, and molecular defects of factor IX. , 1986, Blood.

[13]  A. Tulinsky,et al.  Molecular Interactions of Thrombin. , 1996, Seminars in thrombosis and hemostasis.

[14]  F J Doyle,et al.  Model identification of signal transduction networks from data using a state regulator problem. , 2005, Systems biology.

[15]  K. Mann,et al.  "Normal" thrombin generation. , 1999, Blood.

[16]  Kwang-Hyun Cho,et al.  Experimental Design in Systems Biology, Based on Parameter Sensitivity Analysis Using a Monte Carlo Method: A Case Study for the TNFα-Mediated NF-κ B Signal Transduction Pathway , 2003, Simul..

[17]  Patricia D. Christie,et al.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 1999, Nature Medicine.

[18]  A. Arkin,et al.  Biological networks. , 2003, Current opinion in structural biology.

[19]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. I. An empirical study. , 1994, The Journal of biological chemistry.

[20]  J. Hérault,et al.  The Effect of the Synthetic Pentasaccharide SR 90107/ORG 31540 on Thrombin Generation Ex Vivo Is Uniquely due to ATIII-Mediated Neutralization of Factor Xa , 1995, Thrombosis and Haemostasis.

[21]  M. Petitou,et al.  Chemical synthesis of glycosaminoglycans: new approaches to antithrombotic drugs. , 1991, Nature.

[22]  James R. Knight,et al.  A comprehensive analysis of protein–protein interactions in Saccharomyces cerevisiae , 2000, Nature.

[23]  K. C. Jones,et al.  A Model for the Stoichiometric Regulation of Blood Coagulation* , 2002, The Journal of Biological Chemistry.

[24]  F. Allgöwer,et al.  Robustness properties of apoptosis models with respect to parameter variations and intrinsic noise. , 2005, Systems biology.

[25]  U. Alon,et al.  Robustness in bacterial chemotaxis , 2022 .

[26]  Eduardo Sontag,et al.  Untangling the wires: A strategy to trace functional interactions in signaling and gene networks , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Celia Arnaud.  Systems biology's clinical future , 2006 .

[28]  John Doyle,et al.  Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Ross,et al.  A Test Case of Correlation Metric Construction of a Reaction Pathway from Measurements , 1997 .

[30]  C. Kessler,et al.  Newer concepts of blood coagulation , 1998, Haemophilia : the official journal of the World Federation of Hemophilia.

[31]  Claude,et al.  Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. , 1991, The Journal of clinical investigation.

[32]  Eduardo D. Sontag,et al.  Inferring dynamic architecture of cellular networks using time series of gene expression, protein and metabolite data , 2004, Bioinform..

[33]  J. Stelling,et al.  Robustness of Cellular Functions , 2004, Cell.

[34]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison , 2002, The Lancet.

[35]  E G Tuddenham,et al.  The hemophilias--from royal genes to gene therapy. , 2001, The New England journal of medicine.

[36]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. , 2001, The New England journal of medicine.

[37]  C. Esmon,et al.  The roles of protein C and thrombomodulin in the regulation of blood coagulation. , 1984, The Journal of biological chemistry.

[38]  M Gent,et al.  Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. , 2003, The New England journal of medicine.

[39]  P. Lollar,et al.  Inhibition of activated porcine factor IX by dansyl-glutamyl-glycyl-arginyl-chloromethylketone. , 1984, Archives of biochemistry and biophysics.

[40]  M. Schenone,et al.  The blood coagulation cascade , 2004, Current opinion in hematology.

[41]  Kwang-Hyun Cho,et al.  Dynamics of biological systems: role of systems biology in medical research , 2006, Expert review of molecular diagnostics.

[42]  Nicola J. Rinaldi,et al.  Transcriptional Regulatory Networks in Saccharomyces cerevisiae , 2002, Science.

[43]  N. Roome,et al.  Effects of SanOrg123781A, a Synthetic Hexadecasaccharide, in a Mouse Model of Electrically Induced Carotid Artery Injury: Synergism with the Antiplatelet Agent Clopidogrel , 2004, Journal of Pharmacology and Experimental Therapeutics.

[44]  F. Doyle,et al.  A benchmark for methods in reverse engineering and model discrimination: problem formulation and solutions. , 2004, Genome research.

[45]  G. Feuerstein,et al.  Antithrombotic efficacy of a novel murine antihuman factor IX antibody in rats. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[46]  Olaf Wolkenhauer,et al.  A unified framework for unraveling the functional interaction structure of a biomolecular network based on stimulus‐response experimental data , 2005, FEBS letters.

[47]  L. Greller,et al.  The dynamics of molecular networks: applications to therapeutic discovery. , 2001, Drug discovery today.

[48]  Eduardo Sontag,et al.  Parameter estimation in models combining signal transduction and metabolic pathways: the dependent input approach. , 2006, Systems biology.

[49]  R. Ozawa,et al.  A comprehensive two-hybrid analysis to explore the yeast protein interactome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R J Leipold,et al.  Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin (*) , 1995, The Journal of Biological Chemistry.

[51]  P. Walsh,et al.  Comparative interactions of factor IX and factor IXa with human platelets. , 1989, The Journal of biological chemistry.

[52]  S L Diamond,et al.  Factor VIIa‐mediated tenase function on activated platelets under flow , 2004, Journal of thrombosis and haemostasis : JTH.

[53]  Christer Mattsson,et al.  Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. , 2003, Journal of the American College of Cardiology.

[54]  H. R. Büller,et al.  Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis , 2004 .

[55]  Ildikó Kriszbacher,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.

[56]  S. Leibler,et al.  Robustness in simple biochemical networks , 1997, Nature.

[57]  S. Coughlin,et al.  How the protease thrombin talks to cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Theodore Jardetzky.  HIV: Conformational camouflage , 2002, Nature.

[59]  Skip Brass,et al.  Cardiovascular biology: Small cells, big issues , 2001, Nature.

[60]  H. Büller,et al.  Direct thrombin inhibitors. , 2005, The New England journal of medicine.

[61]  Kumbakonam R. Rajagopal,et al.  A Model Incorporating Some of the Mechanical and Biochemical Factors Underlying Clot Formation and Dissolution in Flowing Blood , 2003 .

[62]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. II. A mathematical simulation. , 1994, Journal of Biological Chemistry.

[63]  John D. Ramsdell,et al.  Estimation of Sparse Jacobian Matrices , 1983 .

[64]  Ken Lo,et al.  Stochastic Modeling of Blood Coagulation Initiation , 2006, Pathophysiology of Haemostasis and Thrombosis.

[65]  K. Mann,et al.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes. , 1990, Blood.

[66]  A. Fogelson,et al.  Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition. , 2001, Biophysical journal.

[67]  J. Stelling,et al.  Robustness properties of circadian clock architectures. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[68]  J. Herbert,et al.  Biochemical and pharmacological properties of SANORG 32701. Comparison with the "synthetic pentasaccharide' (SR 90107/ORG 31540) and standard heparin. , 1996, Circulation research.

[69]  Kenneth G. Mann,et al.  Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation , 1997, The Journal of Biological Chemistry.

[70]  K. Mann,et al.  Blood coagulation. , 2002, Biochemistry. Biokhimiia.

[71]  F. Depasse,et al.  Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma , 2004, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[72]  Bengt I Eriksson,et al.  Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial , 2002, The Lancet.

[73]  John R. Koza,et al.  Reverse Engineering of Metabolic Pathways from Observed Data Using Genetic Programming , 2000, Pacific Symposium on Biocomputing.

[74]  J. Badimón,et al.  Blood-borne tissue factor: another view of thrombosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[75]  B. L. Welch.  The generalisation of student's problems when several different population variances are involved. , 1947, Biometrika.

[76]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[77]  S. Diamond,et al.  Cell Aggregation and Cell Adhesion in Flow , 2002 .

[78]  Sunny Dzik.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation , 2000 .

[79]  Welch Bl.  THE GENERALIZATION OF ‘STUDENT'S’ PROBLEM WHEN SEVERAL DIFFERENT POPULATION VARLANCES ARE INVOLVED , 1947 .

[80]  P. Bork,et al.  Functional organization of the yeast proteome by systematic analysis of protein complexes , 2002, Nature.

[81]  Rudiyanto Gunawan,et al.  Iterative approach to model identification of biological networks , 2005, BMC Bioinformatics.

[82]  Gary D Bader,et al.  Systematic identification of protein complexes in Saccharomyces cerevisiae by mass spectrometry , 2002, Nature.

[83]  Lois Ember.  HOUSE COMMITTEE PASSES BILL , 2006 .

[84]  B. Eriksson,et al.  Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. , 2001, The New England journal of medicine.

[85]  S. Olson,et al.  Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. , 1992, The Journal of biological chemistry.

[86]  Edward G. D. Tuddenham,et al.  The Molecular Genetics of Haemostasis and Its Inherited Disorders , 1994 .

[87]  S L Diamond,et al.  Definitions in biorheology: cell aggregation and cell adhesion in flow. Recommendation of the Scientific Subcommittee on Biorheology of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. , 2002, Thrombosis and haemostasis.

[88]  K. Rajagopal,et al.  A Model for the Formation and Lysis of Blood Clots , 2006, Pathophysiology of Haemostasis and Thrombosis.

[89]  Kenneth G. Mann,et al.  Surface-dependent reactions of the vitamin K-dependent enzyme complexes , 1990 .